Condition 1: nasal polyposis. Condition 2: Chronic rhinitis. Nasal polyp Chronic rhinitis
Conditions
Interventions
Itraconazole capsule of 100 mg, twice per day prescribed for 3 months.(Rose Daru- Tehran- Iran)..
Treatment - Drugs
Itraconazole capsule of 100 mg, twice per day prescribed for 3 months.(Rose Daru- Tehran- Iran).
Sponsors
Isfahan University of Medical Sciences, Vice Challenry
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: The inclusion criteria contained patients at least 15 years old without history of hepatic disease and heart failure; without allergy to Itraconazole, and usage of interacting medications (cisapride, dofetilide, ergot derivatives, levomethadyl lovastatin, midazolam (oral), nisoldipine, pimozide, quinidine, simvastatin, or triazolam). Exclusion criteria of the study were no compliance for follow up; side effects of Itraconazole like rising in hepatic enzyme; nausea, vomiting or starting a new treatment during the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of rhinorrhea, nasal obstruction, hyposmia, dyspnea. Timepoint: 0, 1st, 3rd and 6th months. Method of measurement: Asking the patient about the score of none, mild, moderate and severe. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: 0,1st, 3rd and 6th months. Method of measurement: SNOT-20.;Serum IgE. Timepoint: 0 and 3rd months. Method of measurement: Unit.;Score of CT scan. Timepoint: 0 and 3rd months. Method of measurement: Lund-Mackay scale.;Side effects like elevated liver enzyme, diarrhea and nausea. Timepoint: 0,1st, 3rd and 6th months. Method of measurement: Ask a patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAkram Fereidani
Isfahan University of Medical Sciences
Outcome results
None listed